About Conor McClune

This author has not yet filled in any details.
So far Conor McClune has created 9 blog entries.

Harvest Capital Strategies Raises $245M Fund for Companies Utilizing Tools of Intrexon

Harvest Capital Strategies announced Tuesday that it has raised $245 million to specifically finance companies utilizing the synthetic biology tools of Intrexon Corporation. This is big news for Intrexon, whose subsidiaries and their genetically modified products have been prominent in [...]

LS9 Alumni Found Industrial Microbes and Win G-Prize Contest

One of the big lessons we learned was: No matter how cool a technology is, no matter how well it works and how efficient it is, the underlying economics are essential. Derek Greenfield is explaining to me his path from [...]

Intellia Therapeutics Closes $70M in Series B Funding to Develop CRISPR/Cas9 Therapies

In 2015, nothing excites biotech investors more than CRISPR/Cas9 genome editing technologies. The past 10 months have seen a collective investment of $280 million in CRISPR-focused companies Caribou Biosciences, CRISPR Therapeutics, Editas Medicine, and, as of this week, Intellia Therapeutics. [...]

By | September 4th, 2015|BioPharma & Healthcare, News, Therapeutics|

Prokarium Receives Funding from SynbiCITE to Develop Salmonella-derived Vaccines for Chlamydia

Pathogens have perfected the art of manipulating our immune systems, and Salmonella enterica is one of the best. Prokarium is taking advantage of this natural expertise by re-engineering Salmonella into an efficient vaccine platform for a variety of infectious diseases. [...]

By | August 19th, 2015|BioPharma & Healthcare, Disease Prevention, News|

Ginkgo Bioworks Closes $45M Series B

Shortly after announcing a $9 million series A investment, just four months ago, Ginkgo Bioworks is announcing today that it has raised $45 million in a Series B round led by Viking Global, with participation from previous investors OS Fund, [...]

By | July 23rd, 2015|Industry Providers, News, Organism Engineering Platforms|

Eligo Bioscience Raises €2M to Develop CRISPR Antimicrobials

In recent years, a growing body of research has linked the complex microbial ecologies that inhabit our bodies to diseases ranging from obesity to cancer. However, the ability to directly test hypotheses and to treat microbiome imbalances is hindered by [...]

By | July 16th, 2015|BioPharma & Healthcare, News, Therapeutics|